title: The value of budget impact analyses in evaluating targeted therapies-The case of RSV prophylaxis for preterm infants.
authors.forename: Leonard
authors.initials: L
authors.lastname: Krilov
authors.forename: Deborah
authors.initials: D
authors.lastname: Palazzi
authors.forename: Ancilla W
authors.initials: AW
authors.lastname: Fernandes
authors.forename: Robert
authors.initials: R
authors.lastname: Klein
authors.forename: Parthiv J
authors.initials: PJ
authors.lastname: Mahadevia
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D002017:Budgets; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D017059:Models, Econometric; D058990:Molecular Targeted Therapy / Q000191:economics*; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab